



International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.



Share tweet 0 Email Print

Press Release Source: International Society for Cellular Therapy On Monday August 16, 2010, 6:00 am EDT

VANCOUVER, Aug. 16 /PRNewswire/ - Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.

The ISCT Industry Task Force (ITF), comprising these major corporations along with internationally renowned clinicians and academics in cell therapy translation, rolled out a series of recommendations to re-charter the ISCT Commercialization Committee to drive the creation of forums for discussion of shared concerns on process and product development, business models, and clinical development, and to catalyze the development of consensus standards.

"Working in partnership to develop standards around cell characterization and potency as well as treatment approaches and trial endpoint design we aim to facilitate entry into the cell therapy space for large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced phase clinical trials. Ultimately, this will expedite the maturation of the field and bring cell therapy treatments to patients faster," said Ed Horwitz, M.D., President of ISCT.

These companies remain engaged with ISCT as members on the commercialization committee to drive this agenda forward and are participating in the roll out of the first initiative to add value in the relationship between ISCT and Industry - the new ISCT Industry Community.

The community offers access to key opinion leaders in cell therapy translation including regulatory, scientific, process development and clinical experts through focus group participation, and will drive priorities on the development of resources and initiatives to remove key obstacles to commercialization.

"ISCT is the logical home base for industry stakeholders in the translational medicine space. The commercialization committee is a consortium of institutional, technology, regulatory and industry thought leaders trying to move therapies out of phase I and II. It is poised to be very influential in driving out standards for that process," said Robert Deans, Senior VP Regenerative Medicine Athersys, and Chair of the ISCT Commercialization Committee.

More information on the ISCT ITF recommendations and ISCT Commercialization Committee 2010 deliverables on process and product development, business models, industry education, clinical development and new product introduction can be found at www.celltherapysociety.org/index.php?page=industry

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Established in 1992, its membership and leadership comprises world-class scientists, clinicians, technologists, biotech/pharma and regulatory professionals from around the world focused on pre-clinical and translational aspects of developing cell therapy products.

There are no comments yet

Post a Comment

Top Stories

- The Private Sector Is Hiring. So Why is the Job Market So Bad? - CNBC
- Dow, S&P end flat; volume is lowest of the year - Reuters
- China surges past Japan as No. 2 economy; U.S. next? - AP
- RIM to give India partial BlackBerry access: source - Reuters



Tech Ticker Recent Posts

- One Amusing Difference Between The New Evil Empire (Google) And The Old One (Microsoft) - Henry Blodget
- Hold Onto Your Wallets: Govt., Mortgage Bankers Set to "Fix" Fannie + Freddie - Aaron Task
- Size Matters: The Huge Implications of China's Economic Surge - Aaron Task

[View More](#)

Subscribe to Topics

Top Stories
[MY YAHOO!](#) [RSS](#) [Add Alert](#)

[See all RSS links](#)

ADVERTISEMENT

[Sign in](#) to post a comment, or [Sign up](#) for a free account.

Sponsored Links

5 Unbeatable Stock Picks

Discover How To Make Profits That Could Last A Lifetime.

www.taipanpublishinggroup.com

100% Free Penny Stock Alerts

Get exclusive penny stock alerts set to move up big. Sign up today.

PennyStockAlley.com

These 3 Penny Stocks

Could double next week, get the list of penny stocks ready to move.

www.hototc.com

Free Stock Alerts

Reduce risk levels and potential for loss with alerts from Rethink.

RethinkCapital.com

Copyright © 2010 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

YAHOO! FINANCE

| | |
|---------------------|------------------|
| Banking & Budgeting | Insurance |
| Calculators | Market Stats |
| Currency | Message Boards |
| ETFs | Mobile |
| Experts | Personal Finance |
| Investing | What's New |

ALSO ON YAHOO!

- Autos
- Finance
- Flickr
- Games
- Groups
- Health
- Hot Jobs
- Mail
- Maps
- Movies
- Music
- My Yahoo!

- News
- Shopping
- Sports
- Travel
- TV
- Video

» All Y! Services

THINGS TO DO

- Read Our Blog
- Finance on Your Phone
- Check Home Values
- Find a New Car
- Search Jobs Across the Web

YAHOO! FINANCE WORLDWIDE

Argentina Australia Brazil Canada China Chinese France French Canada Germany

Hong Kong India Italy Japan Korea Mexico New Zealand Singapore Spain Spanish Taiwan UK & Ireland USA

Copyright © 2010 Yahoo! All rights reserved. [Privacy Policy](#) - [About Our Ads](#) - [Terms of Service](#) - [Copyright Policy](#) - [Report Problems](#) - Yahoo! News Network

Quotes delayed, except where indicated otherwise. Delay times are 15 mins for NASDAQ, NYSE and Amex. See also delay times for [other exchanges](#). Quotes and other information supplied by independent providers identified on the Yahoo! Finance [partner page](#). Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.

Fundamental company data provided by [Capital IQ](#). Historical chart data and daily updates provided by [Commodity Systems, Inc. \(CSI\)](#). International historical chart data, daily updates, fundAnalyst estimates data provided by [Thomson Financial Network](#). All data provided by Thomson Financial Network is based solely upon research information provided by third party analysts. Yahoo! has not reviewed, and in no way endorses the validity of such data. Yahoo! and ThomsonFN shall not be liable for any actions taken in reliance thereon.